Laboratory of Pharmaceutical Technology, Ghent University, Belgium.
Eur J Pharm Biopharm. 2013 Nov;85(3 Pt B):1031-8. doi: 10.1016/j.ejpb.2013.05.002. Epub 2013 May 21.
The aim of this study was to investigate the process transfer of a commercially available product from the current batch fluid bed granulation and drying production method to an innovative continuously operating "from powder to tablet" production line using twin screw granulation as an intermediate granulation step. By monitoring process outcomes (torque, water temperature at the granulator jacket inlet, differential pressure over the dryer filters, and temperature mill screen) and granule and tablet quality in function of process time, the stability and repeatability during long production runs were determined. Three consecutive 5h "from powder to tablet" production runs were performed using the ConsiGma™-25 system (GEA Pharma Systems, Collette™, Wommelgem, Belgium). A premix of two active ingredients, powdered cellulose, maize starch, pregelatinized starch, and sodium starch glycolate was granulated with distilled water. After drying and milling (1000 μm and 800 rpm), granules were in-line blended with magnesium stearate and directly compressed using a Modul™ P tablet press (tablet weight: 430 mg, main compression force: 12 kN). Granule (loss on drying, particle size distribution, friability, flow) and tablet (weight uniformity, hardness, thickness, friability, content uniformity, disintegration time, and dissolution) quality was evaluated in function of process time. For each of the logged process outcomes, a stabilization period was needed to reach steady-state conditions. Slightly deviating particle size distribution and friability results for milled granules were observed during start-up due to initial layering of the mill screen. However, no deviating tablet quality was detected in function of process time. For multiple hours, granule and tablet quality was constant in function of process time. Furthermore, process data trends were highly repeatable. Consequently, the ConsiGma™-25 system can be considered as a stable and repeatable system for the continuous production of tablets via wet granulation.
本研究旨在探索将现有批式流化床制粒干燥生产工艺中的商业化产品转移到创新的连续操作“从粉末到片剂”生产线上的过程,采用双螺杆制粒作为中间制粒步骤。通过监测过程结果(扭矩、制粒机夹套入口处的水温、干燥器过滤器的压差以及粉碎机筛网的温度)以及颗粒和片剂质量随过程时间的变化,确定了长时间生产过程中的稳定性和可重复性。使用 ConsiGma™-25 系统(GEA Pharma Systems,Collette™,Wommelgem,比利时)连续进行了三次 5 小时的“从粉末到片剂”生产。使用两种活性成分的预混物、粉末纤维素、玉米淀粉、预胶化淀粉和交联羧甲基纤维素钠与蒸馏水制粒。干燥和粉碎(1000μm 和 800rpm)后,颗粒在线与硬脂酸镁混合,并使用 Modul™ P 压片机直接压缩(片剂重量:430mg,主压缩力:12kN)。评估了颗粒(干燥失重、粒度分布、脆碎度、流动性)和片剂(重量均匀性、硬度、厚度、脆碎度、含量均匀性、崩解时间、溶出度)质量随过程时间的变化。对于每个记录的过程结果,需要达到稳定状态以达到稳定状态。在启动过程中,由于粉碎机筛网的初始分层,观察到粉碎颗粒的略微偏离的粒度分布和脆碎度结果。然而,在过程时间的函数中未检测到偏离的片剂质量。多个小时以来,颗粒和片剂质量随过程时间保持恒定。此外,过程数据趋势具有高度可重复性。因此,ConsiGma™-25 系统可被视为通过湿法制粒连续生产片剂的稳定且可重复的系统。